SupplementsMelatonin

Initiating novel hypnotics in BZRA users reduces BZRA use, but success declines with longer prior BZRA use

In a retrospective cohort study of 190 patients on BZRA hypnotics who initiated novel hypnotics, 46% achieved BZRA reduction at 1 year. Success rates were significantly higher in patients with less than 1 year of prior BZRA use (69%) compared to those with 1 year or more (36%).

Last updated: Jul 28, 2026•0 RCTs•📖 Read as article →

Evidence Score

Evidence Score34/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Long-term effects of introducing novel hypnotics to users of benzodiazepine receptor agonist hypnotics.

observational

Ayani N, Matsumoto Y, Kurokawa T, Nohara C, Kobayashi M, Makino K, Oya N, Kitaoka R, Narumoto J · Sleep medicine (2026)

Participants: N/A
Duration: 1 year
Intervention: Initiation of novel hypnotics (e.g., orexin receptor antagonists, melatonin receptor agonists) in patients already taking BZRA hypnotics
Outcome: Success rate of BZRA hypnotic reduction (by at least one agent) at 1-year follow-up
Effect Size: Odds ratio 0.21 (95% CI: 0.08-0.56) for 1-5 years vs. non-regular use; OR 0.16 (95% CI: 0.06-0.43) for ≥5 years vs. non-regular use
Population: Outpatients at two hospitals in Japan who were on BZRA hypnotics and initiated novel hypnotics from May 1, 2021 to April 30, 2022

Result:

PubMed: 42470902DOI: 10.1016/j.sleep.2026.109148

Mechanism Graph

Patients on BZRAs initiate novel hypnotics as a replacement or adjunct
↓
Novel hypnotics have lower dependence and cognitive impairment risks
↓
Shorter prior BZRA use allows easier transition to novel hypnotics
↓
Result: Higher BZRA reduction success in patients with <1 year of prior use

Limitations

  • ⚠Retrospective design limits causal inference
  • ⚠Single-country study (Japan) may limit generalizability
  • ⚠Small sample size (n=190) for subgroup analyses

Frequently Asked Questions

What are novel hypnotics?▼

Novel hypnotics include orexin receptor antagonists (e.g., suvorexant) and melatonin receptor agonists (e.g., ramelteon), which are considered safer than BZRAs due to lower risk of dependence and cognitive impairment.

How long does prior BZRA use affect the success of switching?▼

Success rates drop sharply: 69% for less than 1 year of prior use vs. 36% for 1 year or more, with odds ratios of 0.21 for 1-5 years and 0.16 for ≥5 years compared to non-regular use.

What was the overall success rate of BZRA reduction?▼

46% of patients achieved reduction of at least one BZRA agent at the 1-year follow-up after initiating novel hypnotics.

Is this study applicable to all insomnia patients?▼

The study was conducted in two Japanese hospitals, so results may not generalize to other populations or healthcare settings without further validation.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Ayani N, Matsumoto Y, Kurokawa T, Nohara C, Kobayashi M, Makino K, Oya N, Kitaoka R, Narumoto J. "Long-term effects of introducing novel hypnotics to users of benzodiazepine receptor agonist hypnotics.." Sleep medicine, 2026. PMID: 42470902 DOI: 10.1016/j.sleep.2026.109148
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.